Close Menu

NEW YORK (GenomeWeb) – Indi Molecular is collaborating with GE Healthcare on Positron Emission Tomography (PET) imaging agents aimed at guiding treatment with cancer immunotherapies.

The companies are developing PET tracers targeting the cell surface protein CD8, allowing for PET imaging-based detection of cytotoxic T lymphocyctes, which have been shown to be predictive of immunotherapy response, said Albert Luderer, CEO and co-founder of Indi Molecular.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.